Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade
Por:
Braso-Maristany F, Griguolo G, Pascual T, Pare L, Nuciforo P, Llombart-Cussac A, Bermejo B, Oliveira M, Morales S, Martinez N, Vidal M, Adamo B, Martinez O, Pernas S, Lopez R, Munoz M, Chic N, Galvan P, Garau I, Manso L, Alarcon J, Martinez E, Gregorio S, Gomis R, Villagrasa P, Cortes J, Ciruelos E, Prat A
Publicada:
20 ene 2020
Resumen:
The HER2-enriched (HER2-E) subtype within HER2-positive (HER2+) breast cancer is highly addicted to the HER2 pathway. However, similar to 20-60% of HER2+/HER2-E tumors do not achieve a complete response following anti-HER2 therapies. Here we evaluate gene expression data before, during and after neoadjuvant treatment with lapatinib and trastuzumab in HER2+/HER2-E tumors of the PAMELA trial and breast cancer cell lines. Our results reveal that dual HER2 blockade in HER2-E disease induces a low-proliferative Luminal A phenotype both in patient's tumors and in vitro models. These biological changes are more evident in hormone receptor-positive (HR+) disease compared to HR-negative disease. Interestingly, increasing the luminal phenotype with anti-HER2 therapy increased sensitivity to CDK4/6 inhibition. Finally, discontinuation of HER2-targeted therapy in vitro, or acquired resistance to anti-HER2 therapy, leads to restoration of the original HER2-E phenotype. Our findings support the use of maintenance anti-HER2 therapy and the therapeutic exploitation of subtype switching with CDK4/6 inhibition.
Filiaciones:
Braso-Maristany F:
Hosp Clin Barcelona, Dept Med Oncol, E-08036 Barcelona, Spain
August Pi & Sunyer Biomed Res Inst IDIBAPS, Translat Genom & Targeted Therapeut Solid Tumors, Carrer Rossello 149-153, Barcelona 08036, Spain
Griguolo G:
Hosp Clin Barcelona, Dept Med Oncol, E-08036 Barcelona, Spain
August Pi & Sunyer Biomed Res Inst IDIBAPS, Translat Genom & Targeted Therapeut Solid Tumors, Carrer Rossello 149-153, Barcelona 08036, Spain
Univ Padua, Dept Surg Oncol & Gastroenterol, Via Giustiniani 2, I-35124 Padua, Italy
IRCCS, Ist Oncol Veneto, Med Oncol 2, Via Gattamelata 64, I-35128 Padua, Italy
Pascual T:
Hosp Clin Barcelona, Dept Med Oncol, E-08036 Barcelona, Spain
August Pi & Sunyer Biomed Res Inst IDIBAPS, Translat Genom & Targeted Therapeut Solid Tumors, Carrer Rossello 149-153, Barcelona 08036, Spain
SOLTI Breast Canc Res Grp, Carrer Balmes 115, Barcelona 08008, Spain
Pare L:
SOLTI Breast Canc Res Grp, Carrer Balmes 115, Barcelona 08008, Spain
Nuciforo P:
Vall dHebron Univ Hosp, Passeig Vall dHebron 119-129, Barcelona 08035, Spain
VHIO, Passeig Vall dHebron 119-129, Barcelona 08035, Spain
Llombart-Cussac A:
Hosp Arnau Vilanova, Carrer St Clement 12, Valencia 46015, Spain
Bermejo B:
Hosp Clin Univ Valencia, Av Blasco Ibanez 17, Valencia 46010, Spain
Oliveira M:
Vall dHebron Univ Hosp, Passeig Vall dHebron 119-129, Barcelona 08035, Spain
VHIO, Passeig Vall dHebron 119-129, Barcelona 08035, Spain
Morales S:
Hosp Arnau Vilanova, Av Alcalde Rovira Roure 80, Lleida 25198, Spain
Martinez N:
Hosp Univ Ramon & Cajal, M-607,Km 9, Madrid 28034, Spain
Vidal M:
Hosp Clin Barcelona, Dept Med Oncol, E-08036 Barcelona, Spain
August Pi & Sunyer Biomed Res Inst IDIBAPS, Translat Genom & Targeted Therapeut Solid Tumors, Carrer Rossello 149-153, Barcelona 08036, Spain
SOLTI Breast Canc Res Grp, Carrer Balmes 115, Barcelona 08008, Spain
Adamo B:
Hosp Clin Barcelona, Dept Med Oncol, E-08036 Barcelona, Spain
August Pi & Sunyer Biomed Res Inst IDIBAPS, Translat Genom & Targeted Therapeut Solid Tumors, Carrer Rossello 149-153, Barcelona 08036, Spain
Martinez O:
Hosp Clin Barcelona, Dept Med Oncol, E-08036 Barcelona, Spain
August Pi & Sunyer Biomed Res Inst IDIBAPS, Translat Genom & Targeted Therapeut Solid Tumors, Carrer Rossello 149-153, Barcelona 08036, Spain
Pernas S:
SOLTI Breast Canc Res Grp, Carrer Balmes 115, Barcelona 08008, Spain
Inst Catala Oncol, Avinguda Gran Via Hospitalet 199-203, Lhospitalet De Llobregat 08908, Spain
Lopez R:
Hosp Clin Univ Santiago, Rua Choupana S-N, Santiago De Compostela 15706, Spain
Munoz M:
Hosp Clin Barcelona, Dept Med Oncol, E-08036 Barcelona, Spain
August Pi & Sunyer Biomed Res Inst IDIBAPS, Translat Genom & Targeted Therapeut Solid Tumors, Carrer Rossello 149-153, Barcelona 08036, Spain
Chic N:
Hosp Clin Barcelona, Dept Med Oncol, E-08036 Barcelona, Spain
August Pi & Sunyer Biomed Res Inst IDIBAPS, Translat Genom & Targeted Therapeut Solid Tumors, Carrer Rossello 149-153, Barcelona 08036, Spain
Galvan P:
Hosp Clin Barcelona, Dept Med Oncol, E-08036 Barcelona, Spain
August Pi & Sunyer Biomed Res Inst IDIBAPS, Translat Genom & Targeted Therapeut Solid Tumors, Carrer Rossello 149-153, Barcelona 08036, Spain
Garau I:
Hosp Son Llatzer, Ctra Manacor, Palma De Mallorca 07198, Spain
Manso L:
Hosp Univ 12 Octubre, Av Cordoba S-N, Madrid 28041, Spain
Alarcon J:
Hosp Univ Son Espases, Carretera Valldemossa 79, Palma De Mallorca 07120, Spain
Martinez E:
Consorcio Hosp Prov Castellon, Av Dr Clara 19, Castellon De La Plana 12002, Spain
Gregorio S:
Inst Res Biomed, Carrer Baldiri Reixac 10, Barcelona 08028, Spain
Gomis R:
Inst Res Biomed, Carrer Baldiri Reixac 10, Barcelona 08028, Spain
Villagrasa P:
SOLTI Breast Canc Res Grp, Carrer Balmes 115, Barcelona 08008, Spain
Cortes J:
VHIO, Passeig Vall dHebron 119-129, Barcelona 08035, Spain
IOB Inst Oncol, Quiron Grp, Placa Alfonso Comin 5, Barcelona 08023, Spain
Ciruelos E:
SOLTI Breast Canc Res Grp, Carrer Balmes 115, Barcelona 08008, Spain
Hosp Univ 12 Octubre, Av Cordoba S-N, Madrid 28041, Spain
Prat A:
Hosp Clin Barcelona, Dept Med Oncol, E-08036 Barcelona, Spain
August Pi & Sunyer Biomed Res Inst IDIBAPS, Translat Genom & Targeted Therapeut Solid Tumors, Carrer Rossello 149-153, Barcelona 08036, Spain
SOLTI Breast Canc Res Grp, Carrer Balmes 115, Barcelona 08008, Spain
|